I think most of that growth will relate to aspects of "commercialization," not to the drug-testing that was the company's sole focus until recently.
Time must be spent discovering/understanding what we currently do not know, we do not know. AVXL will (maybe) be best known for that discovery process when it's history is written.
Joseph why dont you enter the amount of super responders from our Ph 2a with the WT S1 repceptor % and see what chat says about the odds of super responders in our Ph 3 Alzheimer’s trial. This may help put many minds at rest and who knows, maybe it exceeds 76!